Qing Xi Ooi supports clients with hands-on analysis and strategic advice

Viviana Moroso brings scientific depth to quality control

Siv Jönsson develops Pharmetheus’s learning agenda
Events
News

Contact us

Home
About us
People
Anna Mc Laughlin

Anna Mc Laughlin

Anna Mc Laughlin, Dr. rer.nat., MBA

Senior Director, MIDD Consultant

Google scholar

Joined Pharmetheus in 2022, actively working in client projects
Expertise includes model-informed drug development, model-informed precision dosing, and pharmacometrics in therapeutic areas such as oncology, immuno-oncology, and virology
Previously worked as Senior Scientist at Freie Universitaet Berlin, Germany, where she performed pharmacometric research in therapeutic areas such as oncology and immuno-oncology
Pharmacist (2017) and Dr.rer.nat. in Pharmacometrics (2021) from Freie Universitaet Berlin, Germany, and MBA (2025) from Trinity College Dublin, Ireland

Pharmetheus affiliated publications

Model-based Analysis with Mechanistic Insights to CAR-T Cell Therapy Kinetics: Case Study with Axicabtagene Ciloleucel and Brexucabtagene Autoleucel Direct and hybrid machine learning approaches do not outperform NLME-based full Bayesian forecasting for early identification of delayed methotrexate elimination A mechanism-based parsimonious CAR-T cell population PK model and its validation via extension to a population PK-tumor size dynamics model: case study with axicabtagene ciloleucel and brexucabtagene autoleucel Population Pharmacokinetic Analysis of Datopotamab Deruxtecan (Dato-DXd), a TROP2-Directed Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors Development of efficient CAR-T cell clinical study designs: Towards understanding of novel anticancer therapies through optimal experimental design A Bayesian-NLME approach identifies patients at risk of delayed MTX elimination if informative TDM data is provided A mathematical viral load model characterises the exposure- response relationship between bulevirtide and hepatitis delta virus and identifies the minimum duration of on-treatment viral load monitoring required for accurate prediction of long-term virologic response Paediatric pharmacokinetic-pharmacodynamic extrapolation to identify suitable bulevirtide doses for children and adolescents with chronic hepatitis delta Exposure-efficacy analysis of datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, in patients with advanced non-small cell lung cancer Population pharmacokinetic analysis of Datopotamab deruxtecan (Dato-DXd), a TROP2-targeting antibody-drug conjugate A circular PK/PD/PK model explains the exposure of bulevirtide and bile salts in adult patients with Hepatitis D Exploring the relationship between BI 456906 exposure and change in fasting plasma glucose, fasting serum insulin, and glycated hemoglobin (HbA1c) using population PKPD modeling Model-informed drug development of autologous CAR-T cell therapy: Strategies to optimize CAR-T cell exposure leveraging cell kinetic/dynamic modeling Potential strategies to optimize CAR-T cell exposure in absence of dose-exposure relationships leveraging cell kinetic/dynamic models

Contact

Pharmetheus AB
Kungsängstull 4  
753 19 Uppsala, Sweden

Visiting address:  
Dragarbrunnsgatan 77, 5th floor

LinkedIn
YouTube

Services & Science
Quick links

About Pharmetheus

Pharmetheus is a consultancy firm helping clients reduce uncertainty in technical and regulatory processes, increasing confidence in the development of new medicines that can improve patients’ lives.

Whistleblower
Privacy Policy
Cookie Policy